Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pravinkumar Patel

Internal Medicine Fayetteville, NC Medical Doctor

NPI 1669449179 CMS profile 29786

4140 Ferncreek Dr Ste 501, Ferncreek Primary Care, Pc, Fayetteville, NC 28314

Open in the dashboard

General payments

$3,335

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pravinkumar Patel of Fayetteville, NC is reported in the CMS Open Payments database as having received $3,335 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $314 16
2024 General $406 19
2023 General $546 32
2022 General $684 34
2021 General $598 37
2020 General $357 23
2019 General $430 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pravinkumar Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pravinkumar Patel were reported at $314. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pravinkumar Patel Internal Medicine median Middle half National median
2019 $430 $159 $48–$570 $163
2020 $357 $119 $33–$402 $114
2021 $598 $135 $37–$521 $132
2022 $684 $141 $42–$496 $149
2023 $546 $149 $45–$519 $160
2024 $406 $154 $47–$537 $164
2025 $314 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $416 25 payments
  2. Horizon Therapeutics plc $307 20 payments
  3. Exact Sciences Corporation $272 14 payments
  4. AstraZeneca Pharmaceuticals LP $238 12 payments
  5. Novo Nordisk Inc $227 13 payments
  6. Lilly USA, LLC $196 11 payments
  7. Astellas Pharma US Inc $171 6 payments
  8. Pfizer Inc. $155 9 payments
  9. Janssen Pharmaceuticals, Inc $147 10 payments
  10. Merck Sharp & Dohme Corporation $109 7 payments
  11. Other $1,097 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,235 185 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $331 20 payments
  2. Cologuard Collection Kit $224 12 payments
  3. RYBELSUS $210 12 payments
  4. DUEXIS $158 11 payments
  5. XARELTO $147 10 payments
  6. BREZTRI $136 6 payments
  7. BELSOMRA $109 7 payments
  8. AIRSUPRA $108 4 payments
  9. STEGLATRO $98 6 payments
  10. PENNSAID $97 6 payments
  11. Other $2,456 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

8,750

Median for Internal Medicine: 777

Drug cost

$480,387

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 116 $101,431
Rybelsus Semaglutide Brand 39 $62,787
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $39,721
Januvia Sitagliptin Phosphate Brand 31 $33,734
Jardiance Empagliflozin Brand 23 $31,929
Ozempic Semaglutide Brand 16 $20,645
Linzess Linaclotide Brand 13 $16,535
Myrbetriq Mirabegron Brand 20 $16,380
Trulicity Dulaglutide Brand 13 $12,506
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 66 $11,464

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$116,486

Of which drugs: $1,205

Medicare patients

234

Average age 75

Services billed

2,770

139 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 36%
Ischemic heart disease 35%
Chronic kidney disease 24%
Depression 21%
Heart failure 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 44 44 $942
Injection, ketorolac tromethamine, per 15 mg J1885 Office 19 120 $57
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 16 42 $39
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 23 31 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $64
$64 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $49
$49 49 —
Veozah
  • Astellas Pharma US Inc $25
$25 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record